JAGX
JAGX
NASDAQ · Pharmaceuticals

Jaguar Health Inc

$15.45
+12.78 (+478.65%)
As of Sep 22, 6:05 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.15B
Net Income
-5,342,220,413
Gross Margin
67.2%
Profit Margin
-464.2%
Rev Growth
-1.3%
D/E Ratio
3.64
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.2% 67.2% 61.3% 61.3%
Operating Margin -414.4% -373.0% 27.6% 29.3%
Profit Margin -464.2% -441.0% 23.6% 22.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.15B 1.17B 728.2K 878.3K
Gross Profit 773.48M 783.35M 446.4K 538.4K
Operating Income -4,769,681,147 -4,347,491,424 200.8K 257.3K
Net Income -5,342,220,413 -4,869,352,209 171.9K 200.8K
Gross Margin 67.2% 67.2% 61.3% 61.3%
Operating Margin -414.4% -373.0% 27.6% 29.3%
Profit Margin -464.2% -441.0% 23.6% 22.9%
Rev Growth -1.3% -1.3% -5.9% +16.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 7.08M 7.08M 719.4K 546.9K
Total Equity 1.95M 1.95M 1.37M 1.50M
D/E Ratio 3.64 3.64 0.52 0.37
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,578,389,428 -4,404,972,611 249.9K 289.1K
Free Cash Flow 132.1K 184.4K